A. D. Miller

Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.

J. Emerson, R. Gibson, C. Halbert, 2006, Human gene therapy.

Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene

C. Halbert, A. Miller, J. Allen, 2002, Nature Biotechnology.

High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung.

C. Halbert, A. Miller, S. Lam, 2007, Human gene therapy.

Adeno-associated virus types 5 and 6 use distinct receptors for cell entry.

C. Halbert, A. Miller, J. Zabner, 2005, Human gene therapy.

Expression of Human α1-Antitrypsin in Mice and Dogs Following AAV6 Vector-mediated Gene Transfer to the Lungs.

S. Tapscott, C. Halbert, A. Miller, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

AAV-mediated gene transfer to mouse lungs.

C. Halbert, A. Miller, A. D. Miller, 2004, Methods in molecular biology.

Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells

C. Halbert, I. Alexander, G. Wolgamot, 1995, Journal of virology.

Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes

James M. Allen, D. Russell, C. Halbert, 2000, Journal of Virology.

Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6.

C. Halbert, A. Miller, J. Allen, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.